Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib in CML Patients With Molecular Relapse After Imatinib Discontinuation
NCT01774630Phase 2Completed
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Apr 2013
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nilotinib in chronic myeloid leukemia (CML), sponsored by Centre Hospitalier Universitaire de Bordeaux. Started Apr 2013; status: completed.
02
Drugs
nilotinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01774630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01774630.